-
West must embrace 'national power' or face decline: Rubio
-
Kyiv 'cannot agree' to EU membership limiting food exports: minister
-
Shell refining margins reach record highs as wars hit supply
-
Arteta targets more Arsenal glory after signing new deal until 2030
-
Former Spain, Barca winger Pedro retires from football
-
Russell hit with Singapore grid penalty for taking new power unit
-
Arteta signs new Arsenal deal until 2030
-
Spotify expands audiobooks to more than 180 markets
-
Stocks decline as oil climbs on Mideast flareup
-
French-Japanese duo wins chemistry Nobel for solving molecular 'mystery'
-
Gauff says online abuse was 'draining' after China Open exit
-
England's Nations League surge helps heal World Cup wounds
-
As sector struggles, Porsche puts luxury ahead of volume
-
Mayor of opposition stronghold Izmir defects to Erdogan party
-
'It's personal': Fiji minister pushes better climate finance at pre-COP
-
Mertens beats Gauff to set up Swiatek clash at China Open
-
Russia glosses over dark Soviet past in reinvented museum
-
Benin full of pride at role in Messi's last dance
-
UK tax body opened probe into Man City in 2018: FT
-
France suspends stun grenade use at student protests ahead of PM speech
-
Yemen's Houthis claim new attacks on Saudi airports as conflict deepens
-
Indonesian court hears 'negligence' complaint against state over fires, haze
-
Germany factory production at highest level for 18 months
-
Rubio in Greece to urge against Western civilisation 'decline'
-
Thailand floods death toll rises to 60 since mid-September
-
Micron workers at Taiwan plant vote in favour of strike
-
US pushes Russia for information on plague reports
-
In 'The Social Reckoning,' Jeremy Allen White takes on Facebook's 'frightening' ambition
-
Myanmar leader lands in Malaysia for migrant return talks
-
Chip industry activists call for South Korea to recognise cancer cases
-
Indian central bank hikes rates for first time since 2023
-
Famine-scarred southern Madagascar braces for El Nino
-
US military on Okinawa face curfew, alcohol ban after murder case
-
How the EU regulates lobbyists
-
Fierce lobbying in EU over 'forever chemicals'
-
I.Coast refuge offers lifelong care for youngsters scorned as 'sorcerers'
-
Dodgers beat Braves and Padres avoid sweep in MLB playoffs
-
Indian central bank hikes rates for first time in more than 3 years
-
Mourning, war and elections as Israel marks October 7
-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
Baby formula plant linked to US shortage resumes production
Production resumed Saturday at an Abbott Nutrition baby formula plant in the US whose closure helped fuel a crippling nationwide shortage.
The facility in Sturges, Michigan has met initial government sanitary requirements for reopening, the company said in a statement.
The plant shut down in February after the death of two babies, and issued a product recall amid concerns over bacteria contamination.
Shortages of specialized formula were particularly worrying to parents of infants with allergies or with certain metabolic conditions.
Concerns became so acute that President Joe Biden met this week with infant food executives and said his administration was doing everything it could to help.
Abbott said Saturday that it was restarting production of its EleCare formula and that the product should be back on store shelves around June 20.
"We're also working hard to fulfill the steps necessary to restart production of Similac and other formulas," Abbott said.
"We will ramp production as quickly as we can while meeting all requirements."
The United States has been struggling with the shortages for months.
Initially caused by supply chain blockages and a lack of workers due to the pandemic, the shortage was exacerbated when Abbott closed its Sturges plant.
Regulators forced the shutdown amid complaints the plant did not adequately protect against contamination from bacteria.
"Frankly, the inspection results were shocking," FDA chief Robert Califf said last month.
There was standing water in key equipment "that present the potential for bacterial contamination," leaks in the roof and a lack of basic hygiene facilities, he said.
But Abbott officials, while apologizing for the shortage, have said there is no conclusive evidence linking the formula to infant illnesses or deaths.
Abbott's Michigan plant is one of the largest formula factories in the United States.
A.AlHaj--SF-PST